Tiziana Life Sciences Ltd (NASDAQ:TLSA). said it has received positive coverage in an article on Forbes which highlighted foralumab, its unique intranasal monoclonal antibody currently in clinical development to treat multiple sclerosis and other neurodegenerative diseases.
The biotechnology company said that foralumab is the world’s only fully human, anti-CD3 mAb in clinical development. Foralumab binds to the T cell receptor, dampening inflammation by modulating T cell function and suppressing effector features in multiple immune cell subsets.
The company cited the piece by William A Haseltine titled: "New T Cell Antibody Treatment Improves Outcomes for Covid Patients."
READ: Tiziana Life Sciences hails publication in science journal of article on mechanism of action for intranasal foralumab
“Foralumab induces many factors that impact improved tissue remodeling, induction of immune cells, and restriction of effector function, improving disease outcomes while fighting the virus to full strength. These benefits are not limited to Covid-19 patients, as similar results were observed in patients with multiple sclerosis,” the company quoted the Forbes article as saying.
“The anti-CD3 monoclonal treatment effectively modulates the T cell inflammatory response by up or downregulating specific gene and protein expressions, resulting in less severe disease. This novel avenue should be further explored, as more drugs with similar mechanisms could prevent the deaths of thousands,” it quoted the article as saying further.
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.
Contact the author at jon.hopkins@proactiveinvestors.com